2011 - TID Conference


EMERGING TOPICS IN TRANSPLANT ID

3.5 - Novel Advances in Vaccination and Organ Transplant Recipients

Presenter: Oriol, Manuel, Lausanne, Switzerland
Authors: Oriol Manuel, Lausanne, Switzerland


3.5 ‑Novel Advances in Vaccination in Organ
Transplant Recipients
Oriol Manuel, Lausanne, Switzerland

Vaccine-preventable infectious diseases remain a significant problem in immunocompromised patients such as solid-organ transplant (SOT) recipients. For example, the incidence of influenza infection and invasive pneumococcal disease is higher in SOT recipients than in the general population and it is associated with significant morbidity and mortality. The response to vaccination against these pathogens is variable depending on the type of organ transplant and the immunosuppressive regimen used, but overall a reduced immunogenicity after vaccination is expected in SOT recipients. Novel strategies to improve the efficacy of these vaccines are therefore needed. This includes intradermal vaccination, high-dose vaccination and the use of newer adjuvants such as cationic liposomes or toll-like receptors agonists. We will discuss the potential implementation of these strategies in the transplant population.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi